|
1
|
Thomas H, Diamond J, Vieco A, Chaudhuri S,
Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO, et
al: Global Atlas of Cardiovascular Disease 2000-2016: The Path to
Prevention and Control. Glob Heart. 13:143–163. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mortality GBD: Global, regional, and
national age - sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: A systematic analysis for the
Global Burden of Disease Study 2013. Lancet. 385:117–171.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
GBD 2015 Mortality and Causes of Death
Collaborators. Global, regional, and national life expectancy,
all-cause mortality, and cause-specific mortality for 249 causes of
death, 1980-2015: A systematic analysis for the Global Burden of
Disease Study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ross R: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tillett WS and Francis T Jr: Serological
reactions in pneumonia with a non-protein somatic fraction of
pneumococcus. J Exp Med. 52:561–571. 1930.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Taylor AW, Ku NO and Mortensen RF:
Regulation of cytokine-induced human C-reactive protein production
by transforming growth factor-beta. J Immunol. 145:2507–2513.
1990.PubMed/NCBI
|
|
7
|
Thompson D, Pepys MB and Wood SP: The
physiological structure of human C-reactive protein and its complex
with phosphocholine. Structure. 7:169–177. 1999.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pepys MB and Baltz ML: Acute phase
proteins with special reference to C-reactive protein and related
proteins (pentaxins) and serum amyloid A protein. Adv Immunol.
34:141–212. 1983.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shine B, de Beer FC and Pepys MB: Solid
phase radioimmunoassays for human C-reactive protein. Clin Chim
Acta. 117:13–23. 1981.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pepys MB and Hirschfield GM: C-reactive
protein: A critical update. J Clin Invest. 111:1805–1812.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Volanakis JE and Kaplan MH: Interaction of
C-reactive protein complexes with the complement system II.
Consumption of guinea pig complement by CRP complexes: Requirement
for human C1q. J Immunol. 113:9–17. 1974.PubMed/NCBI
|
|
12
|
Claus DR, Siegel J, Petras K, Osmand AP
and Gewurz H: Interactions of C-reactive protein with the first
component of human complement. J Immunol. 119:187–192.
1977.PubMed/NCBI
|
|
13
|
Moutachakkir M, Lamrani Hanchi A, Baraou
A, Boukhira A and Chellak S: Immunoanalytical characteristics of
C-reactive protein and high sensitivity C-reactive protein. Ann
Biol Clin (Paris). 75:225–229. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Calabrò P, Golia E and Yeh ET: CRP and the
risk of atherosclerotic events. Semin Immunopathol. 31:79–94.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Koenig W: High-sensitivity C-reactive
protein and atherosclerotic disease: From improved risk prediction
to risk-guided therapy. Int J Cardiol. 168:5126–5134.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pearson TA, Mensah GA, Alexander RW,
Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y,
Myers GL, et al: Centers for Disease Control and Prevention;
American Heart Association: Markers of inflammation and
cardiovascular disease: application to clinical and public health
practice: A statement for healthcare professionals from the Centers
for Disease Control and Prevention and the American Heart
Association. Circulation. 107:499–511. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ridker PM: Clinical application of
C-reactive protein for cardiovascular disease detection and
prevention. Circulation. 107:363–369. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kaptoge S, Di Angelantonio E, Lowe G,
Pepys MB, Thompson SG, Collins R and Danesh J: Emerging Risk
Factors Collaboration: C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortality: An individual
participant meta-analysis. Lancet. 375:132–140. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jousilahti P, Vartiainen E, Tuomilehto J
and Puska P: Sex, age, cardiovascular risk factors, and coronary
heart disease: A prospective follow-up study of 14 786 middle-aged
men and women in Finland. Circulation. 99:1165–1172.
1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ross R: The pathogenesis of
atherosclerosis: A perspective for the 1990s. Nature. 362:801–809.
1993.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Frostegård J: Immunity, atherosclerosis
and cardiovascular disease. BMC Med. 11(117)2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ridker PM, Cushman M, Stampfer MJ, Tracy
RP and Hennekens CH: Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men. N Engl J Med.
336:973–979. 1997.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Koenig W, Sund M, Fröhlich M, Fischer HG,
Löwel H, Döring A, Hutchinson WL and Pepys MB: C-Reactive protein,
a sensitive marker of inflammation, predicts future risk of
coronary heart disease in initially healthy middle-aged men:
Results from the MONICA (Monitoring Trends and Determinants in
Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation. 99:237–242. 1999.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Danesh J, Whincup P, Walker M, Lennon L,
Thomson A, Appleby P, Gallimore JR and Pepys MB: Low grade
inflammation and coronary heart disease: Prospective study and
updated meta-analyses. BMJ. 321:199–204. 2000.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ridker PM, Hennekens CH, Buring JE and
Rifai N: C-reactive protein and other markers of inflammation in
the prediction of cardiovascular disease in women. N Engl J Med.
342:836–843. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ridker PM: C-reactive protein and the
prediction of cardiovascular events among those at intermediate
risk: Moving an inflammatory hypothesis toward consensus. J Am Coll
Cardiol. 49:2129–2138. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ridker PM, Rifai N, Rose L, Buring JE and
Cook NR: Comparison of C-reactive protein and low-density
lipoprotein cholesterol levels in the prediction of first
cardiovascular events. N Engl J Med. 347:1557–1565. 2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shah PK: Circulating markers of
inflammation for vascular risk prediction: Are they ready for prime
time. Circulation. 101:1758–1759. 2000.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lagrand WK, Visser CA, Hermens WT, Niessen
HW, Verheugt FW, Wolbink GJ and Hack CE: C-reactive protein as a
cardiovascular risk factor: More than an epiphenomenon?
Circulation. 100:96–102. 1999.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Paul A, Ko KW, Li L, Yechoor V, McCrory
MA, Szalai AJ and Chan L: C-reactive protein accelerates the
progression of atherosclerosis in apolipoprotein E-deficient mice.
Circulation. 109:647–655. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen
Y, Fan J and Liu E: C-reactive protein levels are associated with
the progression of atherosclerotic lesions in rabbits. Histol
Histopathol. 27:529–535. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sun H, Koike T, Ichikawa T, Hatakeyama K,
Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, et
al: C-reactive protein in atherosclerotic lesions: Its origin and
pathophysiological significance. Am J Pathol. 167:1139–1148.
2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
de Beer FC, Hind CR, Fox KM, Allan RM,
Maseri A and Pepys MB: Measurement of serum C-reactive protein
concentration in myocardial ischaemia and infarction. Br Heart J.
47:239–243. 1982.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Berk BC, Weintraub WS and Alexander RW:
Elevation of C-reactive protein in ‘active’ coronary artery
disease. Am J Cardiol. 65:168–172. 1990.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zaragoza C, Gomez-Guerrero C,
Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C,
Mas S, Ortiz A and Egido J: Animal models of cardiovascular
diseases. J Biomed Biotechnol. 2011(497841)2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Torzewski M, Waqar AB and Fan J: Animal
models of C-reactive protein. Mediators Inflamm.
2014(683598)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kumar S, Stecher G and Tamura K: MEGA7:
Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger
Datasets. Mol Biol Evol. 33:1870–1874. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang CH, Li SH, Weisel RD, Fedak PW,
Dumont AS, Szmitko P, Li RK, Mickle DA and Verma S: C-reactive
protein upregulates angiotensin type 1 receptors in vascular smooth
muscle. Circulation. 107:1783–1790. 2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hirschfield GM, Gallimore JR, Kahan MC,
Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA and
Pepys MB: Transgenic human C-reactive protein is not proatherogenic
in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA.
102:8309–8314. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kovacs A, Tornvall P, Nilsson R, Tegnér J,
Hamsten A and Björkegren J: Human C-reactive protein slows
atherosclerosis development in a mouse model with human-like
hypercholesterolemia. Proc Natl Acad Sci USA. 104:13768–13773.
2007.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Teupser D, Weber O, Rao TN, Sass K, Thiery
J and Fehling HJ: No reduction of atherosclerosis in C-reactive
protein (CRP)-deficient mice. J Biol Chem. 286:6272–6279.
2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Yu Q, Lin Y, Yang P, Wang Y, Zhao S, Yang
P, Fan J and Liu E: C-reactive protein is associated with the
progression of acute embolic stroke in rabbit model. J Thromb
Thrombolysis. 33:301–307. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yu Q, Liu Z, Waqar AB, Ning B, Yang X,
Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, et al: Effects of
antisense oligonucleotides against C-reactive protein on the
development of atherosclerosis in WHHL rabbits. Mediators Inflamm.
2014(979132)2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Tennent GA, Hutchinson WL, Kahan MC,
Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP and
Pepys MB: Transgenic human CRP is not pro-atherogenic,
pro-atherothrombotic or pro-inflammatory in apoE-/-
mice. Atherosclerosis. 196:248–255. 2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Reifenberg K, Lehr HA, Baskal D, Wiese E,
Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M,
et al: Role of C-reactive protein in atherogenesis: Can the
apolipoprotein E knockout mouse provide the answer? Arterioscler
Thromb Vasc Biol. 25:1641–1646. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Torzewski M, Reifenberg K, Cheng F, Wiese
E, Küpper I, Crain J, Lackner KJ and Bhakdi S: No effect of
C-reactive protein on early atherosclerosis in LDLR-/- /
human C-reactive protein transgenic mice. Thromb Haemost.
99:196–201. 2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Trion A, de Maat MP, Jukema JW, van der
Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM
and Emeis JJ: No effect of C-reactive protein on early
atherosclerosis development in apolipoprotein E*3-leiden/human
C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol.
25:1635–1640. 2005.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Koike T, Kitajima S, Yu Y, Nishijima K,
Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, et al:
Human C-reactive protein does not promote atherosclerosis in
transgenic rabbits. Circulation. 120:2088–2094. 2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pepys MB, Baltz M, Gomer K, Davies AJ and
Doenhoff M: Serum amyloid P-component is an acute-phase reactant in
the mouse. Nature. 278:259–261. 1979.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Fan J, Kitajima S, Watanabe T, Xu J, Zhang
J, Liu E and Chen YE: Rabbit models for the study of human
atherosclerosis: From pathophysiological mechanisms to
translational medicine. Pharmacol Ther. 146:104–119.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kushner I and Feldmann G: Control of the
acute phase response Demonstration of C-reactive protein synthesis
and secretion by hepatocytes during acute inflammation in the
rabbit. J Exp Med. 148:466–477. 1978.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ridker PM, Rifai N, Pfeffer MA, Sacks F
and Braunwald E: The Cholesterol and Recurrent Events (CARE)
Investigators. Long-term effects of pravastatin on plasma
concentration of C-reactive protein. Circulation. 100:230–235.
1999.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hutchinson WL, Koenig W, Fröhlich M, Sund
M, Lowe GD and Pepys MB: Immunoradiometric assay of circulating
C-reactive protein: Age-related values in the adult general
population. Clin Chem. 46:934–938. 2000.PubMed/NCBI
|
|
54
|
Danesh J, Wheeler JG, Hirschfield GM, Eda
S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB and Gudnason V:
C-reactive protein and other circulating markers of inflammation in
the prediction of coronary heart disease. N Engl J Med.
350:1387–1397. 2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Haverkate F, Thompson SG, Pyke SD,
Gallimore JR and Pepys MB: European Concerted Action on Thrombosis
and Disabilities Angina Pectoris Study Group. Production of
C-reactive protein and risk of coronary events in stable and
unstable angina. Lancet. 349:462–466. 1997.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Biasucci LM, Liuzzo G, Grillo RL,
Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G
and Maseri A: Elevated levels of C-reactive protein at discharge in
patients with unstable angina predict recurrent instability.
Circulation. 99:855–860. 1999.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Ridker PM: C-reactive protein and risks of
future myocardial infarction and thrombotic stroke. Eur Heart J.
19:1–3. 1998.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Liuzzo G, Biasucci LM, Gallimore JR,
Grillo RL, Rebuzzi AG, Pepys MB and Maseri A: The prognostic value
of C-reactive protein and serum amyloid a protein in severe
unstable angina. N Engl J Med. 331:417–424. 1994.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ridker PM, Cannon CP, Morrow D, Rifai N,
Rose LM, McCabe CH, Pfeffer MA and Braunwald E: Pravastatin or
Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators.
C-reactive protein levels and outcomes after statin therapy. N Engl
J Med. 352:20–28. 2005.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Ridker PM, Danielson E, Fonseca FA, Genest
J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ,
MacFadyen JG, et al: JUPITER Study Group: Rosuvastatin to prevent
vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 359:2195–2207. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ridker PM, Rifai N, Pfeffer MA, Sacks FM,
Moye LA, Goldman S, Flaker GC and Braunwald E: Cholesterol and
Recurrent Events (CARE) Investigators. Inflammation, pravastatin,
and the risk of coronary events after myocardial infarction in
patients with average cholesterol levels. Circulation. 98:839–844.
1998.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ridker PM, Rifai N, Clearfield M, Downs
JR, Weis SE, Miles JS and Gotto AM Jr: Air Force/Texas Coronary
Atherosclerosis Prevention Study Investigators. Measurement of
C-reactive protein for the targeting of statin therapy in the
primary prevention of acute coronary events. N Engl J Med.
344:1959–1965. 2001.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe
T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C and
Ganz P: Reversal of Atherosclerosis with Aggressive Lipid Lowering
(REVERSAL) Investigators. Statin therapy, LDL cholesterol,
C-reactive protein, and coronary artery disease. N Engl J Med.
352:29–38. 2005.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Bohula EA, Giugliano RP, Cannon CP, Zhou
J, Murphy SA, White JA, Tershakovec AM, Blazing MA and Braunwald E:
Achievement of dual low-density lipoprotein cholesterol and
high-sensitivity C-reactive protein targets more frequent with the
addition of ezetimibe to simvastatin and associated with better
outcomes in IMPROVE-IT. Circulation. 132:1224–1233. 2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: CANTOS Trial Group: Antiinflammatory therapy with
Canakinumab for atherosclerotic disease. N Engl J Med.
377:1119–1131. 2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Jialal I, Devaraj S and Venugopal SK:
C-reactive protein: Risk marker or mediator in atherothrombosis?
Hypertension. 44:6–11. 2004.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Labarrere CA and Zaloga GP: C-reactive
protein: From innocent bystander to pivotal mediator of
atherosclerosis. Am J Med. 117:499–507. 2004.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Verma S, Devaraj S and Jialal I: Is
C-reactive protein an innocent bystander or proatherogenic culprit?
C-reactive protein promotes atherothrombosis. Circulation.
113:2135–2150; discussion 2150. 2006.PubMed/NCBI
|
|
69
|
Pasceri V, Cheng JS, Willerson JT and Yeh
ET: Modulation of C-reactive protein-mediated monocyte
chemoattractant protein-1 induction in human endothelial cells by
anti-atherosclerosis drugs. Circulation. 103:2531–2534.
2001.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Boring L, Gosling J, Cleary M and Charo
IF: Decreased lesion formation in CCR2-/- mice reveals a
role for chemokines in the initiation of atherosclerosis. Nature.
394:894–897. 1998.PubMed/NCBI View
Article : Google Scholar
|
|
71
|
Gu L, Okada Y, Clinton SK, Gerard C,
Sukhova GK, Libby P and Rollins BJ: Absence of monocyte
chemoattractant protein-1 reduces atherosclerosis in low density
lipoprotein receptor-deficient mice. Mol Cell. 2:275–281.
1998.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Pasceri V, Willerson JT and Yeh ET: Direct
proinflammatory effect of C-reactive protein on human endothelial
cells. Circulation. 102:2165–2168. 2000.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Qamirani E, Ren Y, Kuo L and Hein TW:
C-reactive protein inhibits endothelium-dependent NO-mediated
dilation in coronary arterioles by activating p38 kinase and
NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 25:995–1001.
2005.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Devaraj S, Yun JM, Adamson G, Galvez J and
Jialal I: C-reactive protein impairs the endothelial glycocalyx
resulting in endothelial dysfunction. Cardiovasc Res. 84:479–484.
2009.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Hein TW, Singh U, Vasquez-Vivar J, Devaraj
S, Kuo L and Jialal I: Human C-reactive protein induces endothelial
dysfunction and uncoupling of eNOS in vivo. Atherosclerosis.
206:61–68. 2009.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Devaraj S, Kumaresan PR and Jialal I:
C-reactive protein induces release of both endothelial
microparticles and circulating endothelial cells in vitro and in
vivo: Further evidence of endothelial dysfunction. Clin Chem.
57:1757–1761. 2011.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Venugopal SK, Devaraj S, Yuhanna I, Shaul
P and Jialal I: Demonstration that C-reactive protein decreases
eNOS expression and bioactivity in human aortic endothelial cells.
Circulation. 106:1439–1441. 2002.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Verma S, Kuliszewski MA, Li SH, Szmitko
PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW,
et al: C-reactive protein attenuates endothelial progenitor cell
survival, differentiation, and function: Further evidence of a
mechanistic link between C-reactive protein and cardiovascular
disease. Circulation. 109:2058–2067. 2004.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Verma S, Li SH, Badiwala MV, Weisel RD,
Fedak PW, Li RK, Dhillon B and Mickle DA: Endothelin antagonism and
interleukin-6 inhibition attenuate the proatherogenic effects of
C-reactive protein. Circulation. 105:1890–1896. 2002.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Verma S, Wang CH, Li SH, Dumont AS, Fedak
PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, et al: A
self-fulfilling prophecy: C-reactive protein attenuates nitric
oxide production and inhibits angiogenesis. Circulation.
106:913–919. 2002.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Teoh H, Quan A, Lovren F, Wang G, Tirgari
S, Szmitko PE, Szalai AJ, Ward ME and Verma S: Impaired endothelial
function in C-reactive protein overexpressing mice.
Atherosclerosis. 201:318–325. 2008.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Fichtlscherer S, Rosenberger G, Walter DH,
Breuer S, Dimmeler S and Zeiher AM: Elevated C-reactive protein
levels and impaired endothelial vasoreactivity in patients with
coronary artery disease. Circulation. 102:1000–1006.
2000.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Tomai F, Crea F, Gaspardone A, Versaci F,
Ghini AS, Chiariello L and Gioffrè PA: Unstable angina and elevated
c-reactive protein levels predict enhanced vasoreactivity of the
culprit lesion. Circulation. 104:1471–1476. 2001.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Cleland SJ, Sattar N, Petrie JR, Forouhi
NG, Elliott HL and Connell JM: Endothelial dysfunction as a
possible link between C-reactive protein levels and cardiovascular
disease. Clin Sci (Lond). 98:531–535. 2000.PubMed/NCBI
|
|
85
|
Devaraj S, Kumaresan PR and Jialal I:
Effect of C-reactive protein on chemokine expression in human
aortic endothelial cells. J Mol Cell Cardiol. 36:405–410.
2004.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Tabas I, García-Cardeña G and Owens GK:
Recent insights into the cellular biology of atherosclerosis. J
Cell Biol. 209:13–22. 2015.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Calabró P, Willerson JT and Yeh ET:
Inflammatory cytokines stimulated C-reactive protein production by
human coronary artery smooth muscle cells. Circulation.
108:1930–1932. 2003.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Chistiakov DA, Orekhov AN and Bobryshev
YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol
(Oxf). 214:33–50. 2015.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Ryu J, Lee CW, Shin JA, Park CS, Kim JJ,
Park SJ and Han KH: FcgammaRIIa mediates C-reactive protein-induced
inflammatory responses of human vascular smooth muscle cells by
activating NADPH oxidase 4. Cardiovasc Res. 75:555–565.
2007.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Liu N, Liu J, Ji Y, Lu P, Wang C and Guo
F: C-reactive protein induces TNF-α secretion by p38 MAPK-TLR4
signal pathway in rat vascular smooth muscle cells. Inflammation.
34:283–290. 2011.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Liu N, Liu JT, Ji YY and Lu PP: C-reactive
protein triggers inflammatory responses partly via TLR4/IRF3/NF-κB
signaling pathway in rat vascular smooth muscle cells. Life Sci.
87:367–374. 2010.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Cermak J, Key NS, Bach RR, Balla J, Jacob
HS and Vercellotti GM: C-reactive protein induces human peripheral
blood monocytes to synthesize tissue factor. Blood. 82:513–520.
1993.PubMed/NCBI
|
|
93
|
Nakagomi A, Freedman SB and Geczy CL:
Interferon-gamma and lipopolysaccharide potentiate monocyte tissue
factor induction by C-reactive prote in: Relationship with age,
sex, and hormone replacement treatment. Circulation. 101:1785–1791.
2000.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Williams TN, Zhang CX, Game BA, He L and
Huang Y: C-reactive protein stimulates MMP-1 expression in U937
histiocytes through Fc[gamma]RII and extracellular signal-regulated
kinase pathway: An implication of CRP involvement in plaque
destabilization. Arterioscler Thromb Vasc Biol. 24:61–66.
2004.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Ballou SP and Lozanski G: Induction of
inflammatory cytokine release from cultured human monocytes by
C-reactive protein. Cytokine. 4:361–368. 1992.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Torzewski M, Rist C, Mortensen RF, Zwaka
TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V and
Torzewski J: C-reactive protein in the arterial intima: Role of
C-reactive protein receptor-dependent monocyte recruitment in
atherogenesis. Arterioscler Thromb Vasc Biol. 20:2094–2099.
2000.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Reynolds GD and Vance RP: C-reactive
protein immunohistochemical localization in normal and
atherosclerotic human aortas. Arch Pathol Lab Med. 111:265–269.
1987.PubMed/NCBI
|
|
98
|
Yasojima K, Schwab C, McGeer EG and McGeer
PL: Generation of C-reactive protein and complement components in
atherosclerotic plaques. Am J Pathol. 158:1039–1051.
2001.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kobayashi S, Inoue N, Ohashi Y, Terashima
M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, et
al: Interaction of oxidative stress and inflammatory response in
coronary plaque instability: Important role of C-reactive protein.
Arterioscler Thromb Vasc Biol. 23:1398–1404. 2003.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Seifert PS and Kazatchkine MD: The
complement system in atherosclerosis. Atherosclerosis. 73:91–104.
1988.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Torzewski J, Bowyer DE, Waltenberger J and
Fitzsimmons C: Processes in atherogenesis: Complement activation.
Atherosclerosis. 132:131–138. 1997.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Niculescu F, Rus HG and Vlaicu R:
Immunohistochemical localization of C5b-9, S-protein, C3d and
apolipoprotein B in human arterial tissues with atherosclerosis.
Atherosclerosis. 65:1–11. 1987.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Torzewski J, Torzewski M, Bowyer DE,
Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C and Hombach V:
C-reactive protein frequently colocalizes with the terminal
complement complex in the intima of early atherosclerotic lesions
of human coronary arteries. Arterioscler Thromb Vasc Biol.
18:1386–1392. 1998.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Yousuf O, Mohanty BD, Martin SS, Joshi PH,
Blaha MJ, Nasir K, Blumenthal RS and Budoff MJ: High-sensitivity
C-reactive protein and cardiovascular disease: A resolute belief or
an elusive link? J Am Coll Cardiol. 62:397–408. 2013.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Bielas H, Meister-Langraf RE, Schmid JP,
Barth J, Znoj H, Schnyder U, Princip M and von Känel R: C-reactive
protein as a predictor of posttraumatic stress induced by acute
myocardial infarction. Gen Hosp Psychiatry. 53:125–130.
2018.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L,
Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, et al:
C-reactive protein as a predictor of cardiovascular risk in a
population with a high prevalence of diabetes: The Strong Heart
Study. Circulation. 112:1289–1295. 2005.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Hurlimann J, Thorbecke GJ and Hochwald GM:
The liver as the site of C-reactive protein formation. J Exp Med.
123:365–378. 1966.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Eklund CM: Proinflammatory cytokines in
CRP baseline regulation. Adv Clin Chem. 48:111–136. 2009.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Jensen HS: C-reactive protein. Ugeskr
Laeger. 162:2453–2456. 2000.PubMed/NCBI(In Danish).
|
|
110
|
Deban L, Bottazzi B, Garlanda C, de la
Torre YM and Mantovani A: Pentraxins: Multifunctional proteins at
the interface of innate immunity and inflammation. Biofactors.
35:138–145. 2009.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Laskowitz DT, Lee DM, Schmechel D and
Staats HF: Altered immune responses in apolipoprotein E-deficient
mice. J Lipid Res. 41:613–620. 2000.PubMed/NCBI
|
|
112
|
Grainger DJ, Reckless J and McKilligin E:
Apolipoprotein E modulates clearance of apoptotic bodies in vitro
and in vivo, resulting in a systemic proinflammatory state in
apolipoprotein E-deficient mice. J Immunol. 173:6366–6375.
2004.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Li HY, Liu XL, Liu YT, Jia ZK, Filep JG,
Potempa LA, Ji SR and Wu Y: Matrix sieving-enforced retrograde
transcytosis regulates tissue accumulation of C-reactive protein.
Cardiovasc Res. 115:440–452. 2019.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Su HX, Zhou HH, Wang MY, Cheng J, Zhang
SC, Hui F, Chen XZ, Liu SH, Liu QJ, Zhu ZJ, et al: Mutations of
C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal
cancer: Implication for a CRP-Wnt crosstalk. PLoS One.
9(e102418)2014.PubMed/NCBI View Article : Google Scholar
|
